LTRN ▼ -1.3% - Lantern Pharma Inc. $LTRN Lantern Pharma Secures USPTO Notice of Allowance for LP-284 Treatment Patent in Aggressive B-Cell Lymphomas Lantern Pharma shares fell 1.3% despite the company securing a USPTO Notice of Allowance for a patent covering its LP-284 treatment in aggressive B-cell lymphomas, a validation of its intellectual property portfolio in an oncology indication. The modest decline suggests investors may have already priced in the patent milestone or were focused on other near-term catalysts such as clinical trial progress or regulatory timelines. 22-SEP-2026 07:48 AM ET